Sionna Therapeutics宣布推进Sion-451与Sion-2222双重组合疗法进入2a期概念验证试验

美股速递
Yesterday

Sionna Therapeutics今日宣布,计划将其研发中的Sion-451与Sion-2222双重组合疗法推进至2a期概念验证临床试验阶段。这一决定标志着该公司在相关治疗领域迈出了关键性的一步。此次推进的双重组合方案,旨在通过两种药物的协同作用,为患者提供更具潜力的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10